Stock Update (NASDAQ:ENDP): Endo International plc – Ordinary Shares Strengthens Leadership Team with Appointment of Two Key Executives

endpEndo International plc – Ordinary Shares (NASDAQ:ENDP) announced the appointment of two Executive Leadership Team members. Terrance J. Coughlin has been named Executive Vice President and Chief Operating Officer and Tony Pera has been named President, Par Pharmaceutical, which is Endo’s U.S. Generics operating company. Both appointments are effective November 1, 2016.

“I am excited and very pleased to add Terry and Tony to Endo’s Executive Leadership Team and to continue to strengthen the management of the Company,” said Paul Campanelli, President and Chief Executive Officer of Endo. “Terry has worked closely with me over the past 25 years as a partner and collaborator, most recently leading the operations of Par Pharmaceutical. Tony brings experience and expertise that will be tremendously valuable in effectively managing our U.S. Generics business. They are both seasoned and trusted executives who consistently deliver results and I have tremendous confidence in their ability to help drive operational excellence and growth for Endo.”

Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior toEndo’s acquisition of Par in September 2015,  Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc.  Prior to joining Par, Mr. Coughlin held a number of leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited latterly as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited.  Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.

“I am excited and honored to take on this role and look forward to partnering with Paul and our talented senior leadership team as we look to deliver on our goals, including focusing on operational excellence as well as developing and delivering products for patients in need,” said Mr. Coughlin.

Most recently, Mr. Pera served as Chief Commercial Officer of Par Pharmaceutical. He joined Par in February 2014 as part of Par’s acquisition of JHP Pharmaceutical, where he held a similar position. As Chief Commercial Officer, Mr. Pera was responsible for all sales, marketing, pricing and customer operations functions for Par.  Prior to JHP and Par, Mr. Pera was Senior Vice President of Supply Chain Management for AmerisourceBergen (ABC), a major U.S. pharmaceutical wholesaler, for approximately five years. Prior to ABC, he held numerous senior leadership positions with generic drug companies including APP (now Fresenius Kabi), Bedford Laboratories and LyphoMed. Mr. Pera started his career as a sales representative for the parenteral products division of Baxter. He currently serves as the Secretary-Treasurer of the Board of Directors for the Generic Pharmaceutical Association (GPhA). Mr. Pera holds a B.S. in Business Administration from the University of Illinois in Champaign and an M.B.A. from DePaul University.

“This is an important time for the U.S. generics industry, Par and Endo and I am excited to take on this role. I am looking forward to continuing to work closely with Paul and even more collaboratively with the broader Endo Executive Leadership Team to execute and drive success for our Company and to deliver the highest quality, accessible products to the patients we serve,” said Mr. Pera. (Original Source)

Shares of Endo International are up nearly 2% to $15.26 in pre-market trading Monday. ENDP has a 1-year high of $63.71 and a 1-year low of $12.56. The stock’s 50-day moving average is $20.67 and its 200-day moving average is $19.47.

On the ratings front, Endo has been the subject of a number of recent research reports. In a report issued on November 2, Mizuho analyst Irina Rivkind Koffler reiterated a Buy rating on ENDP, with a price target of $29, which represents a potential upside of 94% from where the stock is currently trading. Separately, on October 14, Guggenheim’s Louise Chen reiterated a Buy rating on the stock and has a price target of $35.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Irina Rivkind Koffler and Louise Chen have a yearly average return of 13.8% and a loss of 18.5% respectively. Koffler has a success rate of 44% and is ranked #99 out of 4162 analysts, while Chen has a success rate of 27% and is ranked #3984.

Overall, 5 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $28.00 which is 86.9% above where the stock closed last Friday.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts